

ASX Release

Investor Webinar

PERTH, AUSTRALIA – 18 June 2021: SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to invite shareholders and interested parties to an investor webinar and Q&A hosted by CEO & Managing Director Dr Michael Baker.

The webinar will focus on today's announcement regarding SUDA's global licensing agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy platform. Dr Baker will be joined on the webinar by Professor Anastasios Karadimitris.

The webinar will be held on Monday 21 June 2021 at 4pm AEST.

For the Q&A session, investors are invited to send questions prior to the webinar to matt@nwrcommunications.com.au

Register for the webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_XRQ8daihQiG4hkL6HBe9vw

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone.

Please note a replay of the webinar will be available at the above-mentioned Zoom link shortly following the conclusion of the live session.

For and on behalf of the Board and for further information please contact:

Dr Michael Baker
Chief Executive Officer & Managing Director
SUDA Pharmaceuticals Ltd
Tel: +61 (0) 403 468 187

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit www.sudapharma.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.